Epidemic spread of OXA-48 beta-lactamase in Croatia by Bedenić, Branka et al.
     
 
Središnja medicinska knjižnica 
 
 
 
 
Bedenić B., Slade M., Žele Starčević L., Sardelić S., Vranić Ladavac M., 
Benčić A., Zujić Atalić V., Bogdan M., Bubonja-Šonje M., Tomić-
Paradžik M., Tot T., Lukić Grlić A., Drenjančević D., Varda Brkić D., 
Bandić-Pavlović D., Mihaljević S., Zarfel G., Gužvinec M., Conzemius R., 
Barišić I., Tambić Andrašević A. (2018) Epidemic spread of OXA-48 
beta-lactamase in Croatia.  Journal of Medical Microbiology, 67(8). pp. 
1031-1041. ISSN 0022-2615 
 
 
https://jmm.microbiologyresearch.org/content/journal/jmm 
 
http://dx.doi.org/10.1099/jmm.0.000777 
 
 
 
 
http://medlib.mef.hr/3239 
 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
 
1 
 
EPIDEMIC SPREAD OF OXA-48 BETA-LACTAMASE IN CROATIA 
 
Branka Bedenić1,2, Mia Slade3, Lidija Žele Starčević2, Sanda Sardelić4, Mirna Vranić-
Ladavac5, Ana Benčić1, Vlasta Zujić Atalić6,11, Maja Bogdan6,11, Marina Bubonja-Šonje7, 
Maja Tomić-Paradžik8, Tatjana Tot9 Amarela Lukić-Grlić1,10, Domagoj Drenjančević11, 
Dijana Varda-Brkić2, Daniela Bandić-Pavlović1,2, Slobodan Mihaljević,1,2 Gernot Zarfel12, 
Marija Gužvinec13, Rick Conzemius14, Ivan Barišić14,  Arjana Tambić-Andrašević13 
1School of Medicine, University of Zagreb, Croatia 
2 University Hospital Center Zagreb, Croatia 
3 Croatian Institute of Transfusion Medicine (CITM) 
4University Hospital Center Split, Croatia 
5Public Health Institute of Istria County, Pula, Croatia 
6 Public Health Institute of Osijek-Baranja County, Osijek, Croatia 
7 University of Rijeka, Rijeka, Croatia 
8Public Health Institute Slavonski Brod 
9Department for Microbiology, General Hospital Karlovac 
10Children’s Hospital Zagreb, Croatia 
11School of Medicine, University of Osijek, University Hospital Center Osijek 
12Institute for Microbiology, Hygiene and Environmental Medicine, Medical University of 
Graz, Austria 
13University Hospital for Infectious Diseases, Zagreb, Croatia 
14 AIT, Austrian Institute for Technology, Vienna, Austria 
Type of article: research article 
 
2 
 
Correspondence: Branka Bedenić, Clinical Department for Clinical and Molecular 
Microbiology, School of Medicine, University of Zagreb, University Hospital Center Zagreb, 
tel: +385 1 23 67 304, fax: +385 1 23 67 393, e-mail: Branka.bedenic@kbc-zagreb.hr; 
bbedenic@mef.hr 
 
Key words: Klebsiella pneumoniae, Enterobacter cloacae,  carbapenems, resistance, 
carbapenemase 
 
ABSTRACT 
Purpose: Recently, a dramatic increase of OXA-48 β-lactamase, was observed not only in 
large hospital centers, but also in smaller suburban hospital centers in bordering geographic 
areas of Croatia. The aim of the study was to analyse the epidemiology, the mechanisms of 
antibiotic resistance, and the routes of spread of OXA-48 carbapenemase in Croatia.  
Methods: Carbapenemase, other β-lactamase and fluoroquinolone resistance genes were 
detected by PCR and sequencing. Whole genome sequencing (WGS) was performed on five 
representative isolates. The isolates were genotyped by PFGE.  
Results:  Forty-eight isolates positive for OXA-48, collected in seven hospital centers in 
Croatia from May 2016 to May 2017 were analyzed (forty Klebsiella pneumoniae, five 
Enterobacter cloacae, two Escherichia coli and one Citrobacter freundii).  Thirty-three 
isolates were ESBL positive and harboured  CTX-M group 1  β-lactamase. In addition to the 
β-lactam- resistance genes detected by PCR (blaSHV-1, blaOXA-48 and blaOXA-1),  WGS of five 
representative isolates revealed the presence of genes encoding aminoglycoside resistance 
aadA2 and aph3-Ia, fluoroquinolone resistance determinants aac(6)Ib-c, oqxA and oqxB, the 
sulfonamide resistance gene sul1, and fosA (fosfomycin-resistance). IncL plasmid was found 
in all isolates. Two K. pneumoniae isolates belonged to ST16, two E. cloacae to ST66 and E. 
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coli to ST354. K.  pneumoniae isolates were allocated to five clusters by PFGE which occured 
in different hospitals indicating epidemic spread.  
Conclusions: The OXA-48 positive organisms from this study showed high variability in 
antibiotic susceptibilities, β-lactamase content and PFGE banding patterns. This study 
revealed switch from predominance of VIM-1 in the 2012 to 2013 to OXA-48 in the last two 
years.   
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INTRODUCTION 
Carbapenemases involved in acquired resistance to carbapenems in Enterobacteriaceae 
belong to Ambler class A serin β-lactamases (KPC, GES,  SME,  IMI,  NMC), class B 
metallo-β-lactamases (MBL) of  the IMP, VIM or NDM family and OXA-48-like β-
lactamases belonging to the class D [1-2].  OXA-48 β-lactamase was reported for the first 
time in Turkey in 2004 [3]. In the last decade a remarkable increase of OXA- 48 producing 
organisms was reported in many countries all over the world with the highest rates observed 
in Turkey [4-7]. OXA-48 is the dominant carbapenemase in Germany [8], Portugal [9], 
Romania [10] and Far East [11]. The fast dissemination of the OXA-48 β-lactamase is 
mediated by insertion sequence IS1999 embedded in transposon Tn1999 [12]. Hospital 
outbreaks associated with OXA-48 producing Klebsiella pneumoniae have been reported as 
well [13].  
The first carbapenem–resistant enterobacterial strain  detected in Croatia was NDM-1 
producing K. pneumoniae isolated in the University Hospital Center Zagreb in 2008 [14]. In 
2012 the first KPC-positive K. pneumoniae was reported [15]. A remarkable increase in the 
number of carbapenem-resistant isolates was observed in 2012. This observation gave rise to 
a multicenter study on carbapenem-resistance in Enterobacteriaceae from Croatia, conducted 
in 2011 to 2012 which revealed the predominance of the VIM-1- metallo-β-lactamase  in two 
large hospital centers [16]. There was 36 VIM-1 positive isolates (90%)  among 40 
carbapenemase producing isolates). The remaining three isolates were positive for NDM-1  
and one for KPC-2.   The rate of VIM-1 producing isolates compared to total number of 
carbapenem nonsuceptible isolates was 63% (36/57).  Two years later the clonal outbreak of 
VIM-1 positive Enterobacter cloacae and Citrobacter freundii was observed in the largest 
hospital center in Croatia.  In the same study, the emergence of OXA-48 β-lactamase in 
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Enterobacteriaceae was reported for the first time in two hospital centers in Croatia [17]. In 
total thirty-four E. cloacae isolates were found to possess VIM-1 and were allocated to eight 
clusters with one large clone comprising  eighteen  identical isolates. Seventeen C. freundii 
isolates were identified as VIM-1 producers and they belonged into two clusters with one 
containing eleven identical isolates.  In total  65 patients were infected or colonized  with 
VIM-1 producing organism (14 with K. pneumoniae, 34 with E. cloacae and 17 with C. 
freundii). In that study coexistance of VIM-1, NDM-1 and OXA-48 was reported for the first 
time in Croatia, similarly as previously in India [18]. Four K. pneumoniae and one C. freundii 
were found to harbour VIM-1 and NDM-1 whereas two E. cloacae isolates were positive for 
VIM-1 and OXA-48.Morevoer,  monoclonal outbreak  associated with VIM-1 E. cloacae  (6 
isolates ) was reported in University Hospital Split  in 2012  [19]. VIM-1 was the sole 
carbapenemase  in this hospital center.  
The first OXA-48 producing organisms in Croatia, originating from 2011 to 2012 from 
Nortwest areas of Croatia were reported in the multicenter study performed from 2010 to 
2012 but  published recently  [20]. 
After sporadic cases  during 2010 to 2013 [17,20],  an increase of OXA-48 β-lactamase was 
observed by clinical microbiologists in the participating centers,  not only in large hospital 
centers,  but also in the smaller hospitals in the peripheral, bordering areas of Croatia in the 
last two years.  Since all carbapenem resistant Enterobacteriaceae are sent to the reference 
laboratory for the identification of carbapenemase type, the clinical microbiologist are 
notified about the results of the carbapenemase identification.  They sent only the OXA-48 
producing organisms to the University Hospital Center Zagreb  to analyse the epidemiology, 
the mechanisms of antibiotic resistance, and routes of dissemination of  OXA-48 
carbapenemase in Croatia.  
MATERIAL AND METHODS 
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2.1. Bacterial isolates 
In total 48 enterobacterial isolates were collected from May 2015 to May 2017, from ten 
centers in Croatia which participated in the study: University Hospital Center "Sestre 
Milosrdnice", University Hospital Center Zagreb, University Hospital Center Split, University 
Hospital Center Osijek, University Hospital Center Rijeka, Children’s Hospital Zagreb, 
General Hospital Slavonski Brod, General Hospital Pula, General Hospital Gospić and 
General Hospital Dubrovnik as shown in Fig S1. The isolates were identified to the species 
level by conventional biochemical testing Vitek 2 or  MALDI-TOF, depending on the routine 
laboratory where they were isolated. Only the isolates confirmed as blaOXA-48 positive in the 
Reference center were included in the study. All enterobacterial isolates with reduced 
susceptibility to at least one carbapenem by disk diffusion test, in routine diagnostic 
laboratories in Croatia,  are obliged to be sent to the  Reference Centre for Antibiotic 
Resistance Surveillance in the University Hospital for Infectious Diseases in Zagreb. The 
inhouse Carba NP and commercial test "mastdiscs combi Carba plus (Enterobacteriaceae)" 
were performed to  phenotypically detect  carbapenemases. PCRs targeting the blaVIM, 
blaNDM, blaOXA-48 and blaKPC genes was conducted for the isolates positive in the phenotypic 
tests. The clinical microbiologists in the routine laboratories are notified by the reference 
laboratory about the type of carbapenemase and the isolates confirmed to possess OXA-48 
were sent to the Clinical Department for Clinical and Molecular Microbiology of the 
University Hospital Center Zagreb for further analysis.   
All other analysis of isolates (sections 2.2, 2.3, 2.4, 2.6, 2.7. and 2.8) including antimicrobial 
susceptibility testing, phenotypic detection of β-lactamases,  molecular detection of other β-
lactamases,  qnr genes,  and insertion sequence, plasmid characterization and genotyping was 
done in the Clinical Department for Clinical and Molecular Microbiology, University 
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Hospital Center Zagreb.  Whole genome sequencing was done at the Austrian Institute for 
Technology.  
2.2. Antimicrobial susceptibility testing and phenotypic tests for detection of ESBLs, plasmid-
mediated AmpC β-lactamases and carbapenemases 
The antimicrobial susceptibility to amoxicillin alone and combined with clavulanate, 
piperacillin/tazobactam, cefazoline, expanded- spectrum cephalosporins or ESC (ceftazidime, 
cefotaxime, ceftriaxone), cefepime, imipenem, meropenem, ertapenem, gentamicin, 
ciprofloxacin and colistin was determined by the broth microdilution method according to 
CLSI standards [21] and for colistin according to the EUCAST standard 
(Http://www.eucast.org). The susceptibility to fosfomycin was determined by agar dilution. E. 
coli ATCC 25922 and K. pneumoniae 700603 were used as quality control strains for 
minimum inhibitory concentration (MIC) determination.  The susceptibility to 
sulphametoxazole/trimethoprim, tetracycline and chloramphenicol was determined by disk-
diffusion test. The isolates were classified as multidrug-resistant (MDR), extensively drug-
resistant (XDR) or pandrug-resistant (PDR)  as described previously by Magiorakos et al [22]. 
The double disk synergy test (DDST) [23] and the CLSI combined disk test with addition of 
clavulanic acid were performed to detect ESBLs [21]. Chromosomal or plasmid-mediated 
AmpC β-lactamases were detected by combined disk test using cephalosporin disks with 3-
aminophenylboronic acid (PBA) [24]. A modified Hodge test (MHT) and the carbapenem-
inactivation method (CIM) were used to screen for the presence of carbapenemases [25-26]. 
Additionally, the isolates were tested by combined disk tests with imipenem and meropenem 
alone and combined with PBA, 0.1 M EDTA or both to screen for KPC, MBLs, or 
simultaneous production of KPC and MBL, respectively [27, 28].  
2.3. Molecular detection of resistance genes 
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The genes conferring resistance to β-lactams, including broad spectrum and extended-
spectrum β-lactamases (blaSHV, blaTEM, blaCTX-M, blaOXA-9, blaOXA-1 and blaPER-1), plasmid-
mediated AmpC β-lactamases, class A (blaKPC, blaSME, blaIMI, blaNMC), class B 
carbapenemases (blaVIM, blaIMP and blaNDM), carbapenem hydrolyzing oxacillinases (blaOXA-
48-like ) and fluoroquinolone resistance genes (qnrA, qnrB, qnrS) were determined by PCR 
using protocols and conditions as described previously [29-36]. Group of  CTX-M β-
lactamases was detected by multiplex PCR [33].  The inactivation of mgrB genes and plasmid 
encoded colistin resistance genes mcr-1 were analyzed in two isolates with reduced 
susceptibility to colistin by PCR as described previously [37-38]. β-lactamase encoding PCR 
amplification products  from nine representative  isolates from each center  (K. pneumoniae 
16780 from Pula, VG-8166 from Zagreb, OS2 and OS8 from Osijek, UHC 1900807 from 
Zagreb, UR 22272 from Split, E. cloacae 17504 from  Pula, E. cloacae 30676 from Slavonski 
brod, and E. coli 18464 from Pula)  were subjected to sequencing to determine the allelic gene 
variant of the TEM, SHV and CTX-M β-lactamases.  The positive control strains producing 
TEM-1, TEM-2 and SHV-1 and SHV-2 were kindly provided by Prof. Adolf Bauernfeind 
(Max von Pettenkofer Institute, Munich, Germany), CTX-M-15 by Prof. Neil Woodford 
(Health Protection Agency, London, UK) and OXA-48 by Dr. Yvonne Pfeifer (Robert Koch 
Institute, Wernigerode, Germany). PCR mapping was performed with primers for IS1999 
combined with forward and reverse primers for blaOXA-48 [12].  The size of the product was 
determine by the gel electrophoresis, after staining with ethidium bromide.  The amplification 
products from selected strains (E. cloacae 17504,  K. pneumoniae 7210,   K. pneumoniae 
22272, K. pneumoniae 17068, K. pneumoniae 24889 and K. pneumoniae 332-1 were 
sequenced by a commercial supplier ( Eurofin Germany) in order to analyse the genetic 
context of the  blaOXA-48 genes and the position of genes flanking blaOXA-48. Genetic context of 
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blaCTX-M genes was determined by PCR mapping with forward primer for ISEcp1  and IS26 
combined with primer MA-2 (reverse for blaCTX-M genes) [39].  
2.4. Conjugation and transformation 
The transferability of meropenem and cefotaxime resistance was determined by conjugation 
(broth mating method) at 35°C employing E. coli J65 recipient strain resistant to sodium- 
azide [40]. The transconjugants  were selected on MacConkey agar containing either 
meropenem (0.5 mg/L) or  cefotaxime (2 mg/L) and sodium azide (100 mg/L). The frequency 
of conjugation was determined relatively to the number of donor cells. Cotransfer of 
resistance to gentamicin, tetracycline, sulfamethoxazole/trimethoprim, chloramphenicol and 
ciprofloxacin was determined. The isolates which did not yield transconjugants were 
subjected to transformation experiment   as described previously [41]. Plasmids  were 
extracted with Macherey Nagel- Nucleospin kit  (Macherey-Nagel, Gmbh, Germany) and  
transferred to CaCl2 treated E. coli A15R- recipient strain.  Transformants were selected on 
MacConcey medium containing 1 mg/L of meropenem.  
2.5.Whole genome sequencing (WGS) 
WGS was done in Austrian Institute for Techology. Five representative OXA-48 producing 
isolates belonging to different species and hospital centers were selected for further WGS. K 
pneumoniae OS2 (ESBL negative), K. pneumoniae OS5 (ESBL positive), both from Osijek, 
E. cloacae 30676 from Slavonski Brod (ESBL positive), E. cloacae 17604 from Pula (ESBL 
negative) and E. coli 18464 (ESBL negative) from Pula. The bacterial genomes were 
sequenced using the IonTorrent PGM platform (Life Technologies, Carlsbad, USA) according 
to the manufacturer's instructions. The Ion Xpress Plus Fragment Library Kit was used to 
enzymatically shear 100 ng of the genomic DNA. The target fragment size was 400 bp. 
Subsequently, the fragmented DNA was processed using the Ion DNA Barcoding kit (Life 
Technologies) and its size selected using the E-Gel SizeSelect 2% Agarose kit (Life 
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Technologies). The size distribution of the DNA fragments was analysed using the High 
Sensitivity Kit (Agilent, Santa Clara, USA). Further sample processing was performed using 
the Ion OneTouch Kit (Life Technologies). Finally, the amplified DNA was sequenced using 
the 318 chip (Life Technologies). The single reads obtained were de novo assembled using 
MIRA 3.9.9, which is part of the Assembler plug in on the Ion Torrent server. Subsequently, 
the contigs were analyzed using the RAST analysis platform and the ResFinder web-service 
to screen for antibiotic resistance genes and their genetical context [42]. 
2.6. Characterization of plasmids 
Plasmids were extracted from donor strains and their respective transconjugants with Machery 
Nagel nucleospin kit according to the manufacturer’s instructions. After staining with 
ethidium bromide, the DNA was visualised by ultraviolet light. PCR-based replicon typing 
(PBRT) [43] was applied to determine the plasmid content of the tested strains. Since it was 
observed previously that PBRT can be inefficient in identifying L/M plasmid type, an updated 
method designated to identify and distinguish between IncL and IncM  plasmids was applied  
[44]. Plasmid extractions obtained from transconjugant strains were subjected to PCR for the 
detection of OXA-48 and  ESBLs  in order to determine  the resistance gene content of the 
transconjugants. PBRT was also applied on transconjugants to identify incompatibility groups 
such as in their respective donors.   Positive control strains for PBRT were kindly provided by 
dr. A. Carattoli (Insituto Superiore di Sanita, Rome, Italy).  
2.7. Pulsed-field gel electrophoresis (PFGE) 
Thirty-nine K. pneumoniae, and all E. cloacae and E. coli isolates were subjected to 
genotyping by PFGE. One K. pneumoniae isolate died before PFGE was finished.  PFGE 
genotyping of XbaI-digested genomic DNA was performed with a CHEF-DRIII system (Bio-
Rad); the images were processed using the Gel-Compar software. The dendrogram was 
computed after band intensity correlation using global alignment with 1.5 % optimization and 
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1% tolerance and unweighted pair-group method using arithmetical averages (UPGMA) 
clustering. PFGE cluster analysis was carried out with Gel Compare II (Applied Maths, 
Belgium) using Dice similarity coefficient and clustering by the UPGMA [45]. Band patterns 
were visually compared to define indistinguishable and closely related subtyped differing by 
two or three bands, in accordance with the criteria proposed by Tenover [46].  Each PFGE 
cluster was assigned a roman number followed by a letter indicating closely related isolates. 
The K. pneumoniae clusters have been designated as K and E. cloacae as E.  
12 
 
RESULTS 
2.1. Bacterial isolates 
Thirty-six  patients had an infection with an isolate comprising OXA-48,  whereas twelve of  
the patients were only colonized.  The type of infection, antibiotic treatment and outcome are 
shown in Table 1a and b. Urinary tract infection was the predominant type of infections (14 
patients), followed by pneumonia (eight patients), septicaemia (four patients),  wound 
infections (three patients), osteomyelitis (two patients), peritonitis (two patients) and otitis 
media (one patient).  For two patients the data were not available.  
In total 48 isolates were analysed in the study: twenty-five from University Hospital Center 
Osijek, eight from University Hospital Center Split, six from General Hospital Pula, four from 
General Hospital Slavonski Brod, two from University Hospital Center Zagreb and University 
Hospital Center "Sestre Milosrdnice", respectively and one from University Hospital Center 
Rijeka as shown in Fig. S  1 (Supplementary material). Out of 48 isolates, 40 were K. 
pneumoniae, five E. cloacae, two E. coli and one C.  freundii.  
The Children’s Hospital in Zagreb, General Hospital Gospić and General Hospital Dubrovnik 
did not detect any OXA-48 positive organisms in the study period. Twenty-one isolates were 
obtained from the patients with the infection and the rest from colonized patients. The 
Children’s Hospital in Zagreb, General Hospital Gospić and  General Hospital Dubrovnik did 
not have any OXA-48 positive organisms in the study period (May 2015 to May 2017). The 
rate of carbapenem resistant Enterobacteriaceae varied from 0,03% in Dubrovnik to 4% in 
University Hospital Center Zagreb in the period May 2015 to May 2017. The rates were as 
follows: 0,03 % (4/12361) in Dubrovnik, - 0.04% (6/13 937) in Pula, - 0.09% (8/8151)  in 
University Hospital Rijeka, -0.4% (16/3834) in Children’s Hospital Zagreb, -0.68% (48/7053) 
in University Hospital Center Osijek,  -0.9% (29/3181), in General Hospital Slavonski Brod  -
1% (93/8958) in University Hospital  Center Split and - 4% (355/8806) in University Hospital 
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Zagreb. The University Hospital „Sestre Milosrdnice“ does not have a surveillance system 
and the data on the total number of Enterobacteriaceae are not available. An association with 
the resistance rate and hospital size was observed. The large hospitals such as University 
Hospital Center Zagreb and University Hospital Split with bone marrow and kidney 
transplantation wards had higher resistance rates.  
The rate of OXA-48 producing organisms among carbapenem- resistant Enterobacteriaceae 
was as follows: 0.01% (1/8) in University Hospital Center Rijeka, 13% (47/355) in University 
Hospital Center Zagreb, 14% (4/29) General Hospital Slavonski Brod, 15% (14/93) in 
University Hospital Center Split, 50% (24/48) in University Hospital Center  Osijek and 
100% (6/6)  in General Hospital Pula. Fifteen patients died and the other twenty-one 
recovered from infection.   Various antibiotic combinations, including meropenem, colistin 
and amikacin were used for the treatment (Table 1 and and 1b).  Meropenem was the most 
frequently prescribed antibiotic, administered in fifteen cases. 
2.2. Antimicrobial susceptibility testing and phenotypic tests for detection of ESBLs, plasmid-
mediated AmpC β-lactamases and carbapenemases 
All isolates were uniformly resistant to amoxicillin, amoxicillin/clavulanate, 
piperacillin/tazobactam and cefazoline. K. pneumoniae isolates showed high resistance rates 
to ertapenem and ciprofloxacin (82.5%), expanded-spectrum cephalosporins (ESC) (67.5%), 
meropenem (47.5%), cefepime (45%), and imipenem (37.5%). Gentamicin and colistin 
preserved good activity with 85% and 98% susceptible K. pneumoniae isolates, respectively, 
as shown in Table 1a. Eleven out of 40 isolates (27%) were resistant to fosfomycin. Twenty-
four isolates (60%) were resistant to sulfamethoxazole/trimethoprim and eight (20%) to 
tetracycline. E. cloacae were uniformly resistant to amoxicillin alone and combined with 
clavulanate, piperacillin/tazobactam, cefazoline, expanded-spectrum cephalosporins and 
cefepime (Table 1b). Four out of five isolates (80%) were resistant to ciprofloxacin and 
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gentamicin. Three (60%) isolates were resistant to imipenem and meropenem. One isolate 
(2.5%) displayed resistance to fosfomycin. Resistance to sulfamethoxazole/trimethoprim, 
tetracycline and chloramphenicol was recorded in  three isolates.   
The two E. coli isolates were susceptible to ESC, cefepime and colistin and resistant to 
ciprofloxacin as shown in Table 1b. They exhibited variable MICs of carbapenems.  One 
isolate was resistant to sulfamethoxazole/trimethoprim and tetracycline. A C. freundii  isolate 
was susceptible to all tested antibiotics except of amoxicillin alone and combined with 
clavulanate and piperacillin (Table 1b). In summary,  thirty- one isolates were MDR and two 
were XDR (OS21 and 24889) since they were resistant to colistin as well (MIC values of 64 
and 128 mg/L, respectively). The MDR phenotype was associated with the production of an 
additional ESBL.  
Twenty-eight out of 40 K. pneumoniae and all E. cloacae isolates were phenotypically 
positive for ESBL (Table 1a and b). Inhibitor- based test with PBA for detection of AmpC- β-
lactamases was positive in four E. cloacae, one C. freundii and four K. pneumoniae isolates. 
Hodge- test for the detection of carbapenemase activity was positive in all isolates whereas 
CIM yielded negative results in six OXA-48 producing K. pneumoniae  isolates (12%) (Table 
1a).  Two  (VG 8166 and OS5)  of the six CIM negative isolates were resistant only to 
ertapenem with MIC value of 16 mg/L and 4 mg/L, respectively. One isolate (VG 16/3885) 
was susceptible only to imipenem with a MIC value of 0.5 mg/L,  whereas the other two 
(OS4, 158889)  were resistant to all three carbapenems with MIC values ranging between 32 
mg/L and 64 mg/L.  One isolate (OS 13) was fully susceptible to all three carbapenems with 
MIC values equal or below 1 mg/L as shown in Table 1 a.  
2.3.  Molecular detection of resistance genes 
All twenty- eight ESBL and OXA-48 producing K. pneumoniae harboured group 1-CTX-M 
β-lactamase. Sequencing of representative amplication products from each center revealed the 
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presence of the blaCTX-M-15 (Table 1a). blaCTX-M-15 genes were preceded by an ISEcp insertion 
sequence. Twelve CTX-M producing isolates harboured in addition to OXA-48 also TEM-1 
and three OXA-1 (Table 1a). All OXA-48 and ESBL positive E. cloacae produced  group 1-
CTX-M- ESBL plus an additional TEM-1 and OXA-1 in two isolates, respectively (Table 1b). 
The E. coli isolates possessed only OXA-48 combined with the broad spectrum TEM-1 β-
lactamase in one isolate (Table 1b). A C. freundii isolate possessed chromosomal CMY in 
addition to OXA-48 (Table 1b). Genes QnrA and QnrB, contributing to fluoroquinolone 
resistance, were found in two and twenty isolates, respectively. K. pneumoniae was the 
dominant species carrying qnr genes (19 out of 20). The mcr-1 gene, contributing to colistin 
resistance, was not found in the colistin-resistant K. pneumoniae isolates. Other species did 
not show colistin resistance.  
PCR analysis detected wildtype mgrB genes.  PCR mapping revealed augmentation of the 
PCR product obtained with forward primer for IS1999 and reverse for blaOXA-48 gene, 
compared to the size of the PCR product obtained with the primers for IS1999.  An analysis 
of the genetic context of selected strains revealed the presence of IS1999, IS1R and tnpA 
upstream of the blaOXA-48 gene and lysR, IS1999 and tnpA downstream of the blaOXA-48 gene.   
2.4. Conjugation and transformation 
 Reduced susceptibility to meropenem of thirty-one isolates was transferred to E. coli 
recipient strain with the frequency ranging from 1.2 to 8.4 x 10-6 . Sixteen out of 33 ESC 
resistant isolates transferred cefotaxime resistance to E. coli recipient with the frequency 
ranging from 8x10-8 to 4 x10-4. The transconjugants obtained with cefotaxime as selective 
agent showed similar resistance patterns to ESC as their respective donors. Resistance to 
sulphametoxazole was cotransferred alongside with cefotaxime resistance in six and to 
tetracycline in two tested isolates which transferred cefotaxime resistance. The 
transconjugants obtained with meropenem as selective agent did not harbour resistance genes 
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to sulphonamides, tetracyclines, chloramphenicol or gentamicin. The sixteen tranconjugants 
obtained with cefotaxime as selective agent harboured blaCTX-M genes as their respective 
donors.  Thirty-one transconjugants obtained with meropenem as selective agent possessed 
blaOXA-48 genes.  The remaining 17 isolates which did not transfer meropenem resistance in 
conjugation experiments were subjected to transformation but transformants were not 
obtained.  
2.5. Whole genome sequencing  
WGS of five  representative isolates  (K. pneumoniae n=2, E. cloacae n=2 and E. coli, n=1) 
revealed the presence of genes encoding aminoglycoside resistance aadA2 and aph3-Ia, 
fluoroquinolone resistance determinants aac(6)Ib-c (The aminoglycoside acetyltransferase 
 Aac(6')-Ib-cr variant, an enzyme usually encoded by a plasmid-borne gene, extends its drug 
targets to include fluoroquinolones  in addition to aminoglycosides), oqxA and oqxB 
sulfonamide resistance gene sul1, fosA (fosfomycin modifying enzymes) encoded fosfomycin 
resistance and the β-lactamase genes blaSHV-1, blaOXA-48 and blaOXA-1 in the K. pneumoniae 
isolates OS2 and OS8 from Osijek.  E. cloacae 30676 from Slavonski Brod and E. cloacae 
17504 from Pula possessed aac(6')Ib-cr, aph(6)-Id, aph(3'')-Ib, aph(3'')-Ib and aac(3)-Iia in 
addition to the blaACT-7 and blaTEM-1b gene. 
The E. coli 18464 from Pula possessed the aminoglycoside resistance genes aac(3-)Iid, 
aph(3'')-Ib, aph(6)-Id and aph3-Ib, tetracycline resistance gene tet(B), trimethoprim resistance 
gene drfA17 and sulfonamide resistance gene sul2, fosA encoded fosfomycin resistance and 
the β-lactamase genes blaOXA-48 and blaTEM-1b. The presence of blaOXA-48 gene flanked with 
IS1999 sequences was confirmed. BLAST analyses of the contigs comprising the blaOXA-48 
gene with 100% sequence similarity resulted in hits from plasmid associated NCBI entries. 
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Two K. pneumoniae isolates (OS2 and OS 8) belonged to ST16, two E. cloacae (30676  and 
17604)  to  ST66 and the E. coli 18464 isolate could not be assigned precisely to a known 
sequence type. The two most closely related were ST354 and ST39.  
2.6. Plasmid characterization 
A plasmid of 60 to 70 kb was visible in donor and tranconjugant strains. All plasmid 
extractions from donor strains yielded L plasmids by PCR with the modified method 
according to Carattoli [45].  The PCR for L/M plasmid was negative.  The transconjugants 
obtained with meropenem as selective agent harboured L plasmid as their respective donors.  
2.7.Pulsed-field gel electrophoresis (PFGE)  
Genotyping revealed the existence of five clusters among  thiry-nine K. pneumoniae isolates 
which contained subclusters  with highly similar isolates. The largest cluster was the clone I 
which contained 19 isolates allocated to eight subclones, each comprising isolates originating  
predominantly from Osijek and Split, with one strain isolated in Pula (Fig. S  2a-
supplementary material) . Isolates originating from different hospital wards in the same center 
and with different  β-lactamase content, including ESBL positive and ESBL negative, 
clustered together. The second cluster contained eight isolates, arranged  in three subclusters 
with isolates obtained from five hospital centers (Split, Osijek, Pula, Slavonski Brod and 
University Hospital “Sestre Milosrdnice” in Zagreb), from different specimens and hospital 
wards,   whereas the third cluster comprised  five  isolates; from four different hospital centers  
(University Hospital “Sestre Milosrdnice” , Rijeka, University hospital Center Zagreb, Osijek 
and Rijeka) .  Cluster IV and cluster V comprised only two isolates, respectively.  Three 
isolates (OS 9,  OS 13 and KK3602)   had unique banding patterns and  were designated as 
singletons (Fig. S  2a-supplementary material). The isolates belonging to one cluster in one 
hospital were usually from the same period but included different hospital wards indicating 
cross infection.  
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All five E. cloacae isolates from different centers (Pula, Slavonski Brod, Osijek and Split) 
were allocated to cluster  E I and showed >85% similarity but some diversification was 
observed within the clones and thus four subclusters were identified (Fig. S 2b-supplementary 
material).  
Two E. coli isolates showed different banding patterns.  
 
DISCUSSION 
After the first report of OXA-48 in the large hospital centers in Croatia in 2012, the clinical 
microbiologist in smaller hospitals in peripheral, bordering geographic areas of Croatia have 
noticed a dramatic increase of OXA-48 among carbapenem-resistant Enterobacteriacae 
according to the data from the Reference Centre for Antibiotic Resistance Surveillance in the 
University Hospital for Infectious Diseases in Zagreb, from 0% until 2014 to almost 100% in 
the last two years, depending on the center .  
Croatia has a national surveillance system and specific guidelines for the management of 
carbapenemase- producing Enterobacteriaceae and obligation to report them to the health 
authorities, but in spite of these measures there is an increase of OXA-48 producing 
organisms, similarly as in other European countries. The production of ESBL, predominantly 
belonging to the CTX-M family, was associated with resistance to ESC.  Gentamicin and 
fluoroqinolones exhibited resistance in ESBL positive isolates due to the additional qnr genes 
usually located at the same plasmid. All isolates showed a high level of resistance to 
amoxycillin/clavulanate and piperacillin/tazobactam which is typical for OXA-48 β-lactamase 
since it hydrolyzes penicillins and similarly as other OXA β-lactamases is not inhibited by 
clavulanic acid or tazobactam. The production of additional OXA-1 β-lactamase in some of 
the isolates may have contributed to the resistance to β-lactam combinations with inhibitors.  
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The isolates exhibited variable MICs of carbapenems, probably due to variable levels 
expression of blaOXA-48 genes which could be attributed to different gene copy or plasmid 
copy numbers. All isolates showed reduced susceptibility to ertapenem in disk-diffusion test 
and this was used to screen for carbapenemase production. The low level of carbapenem-
resistance in some OXA-48 producing organisms pose a serious problem for detection of this 
increasingly important carbapenem resistance determinant. For that reason microbiologists 
rely on phenotypic tests. Hodge test showed high sensitivity of 100%  in detection of OXA-48 
β-lactamase in contrast to CIM test which showed false negative results in 12%  isolates. The 
isolates negative in CIM test exhibited variable carbapenem MICs. The Carba-NP test is 
recommended as a sensitive test for the detection of carbapenemases, but the drawback of this 
method is a high cost [47]. 
Colistin resistance observed in two K. pneumoniae isolates was not associated with the 
inactivation of mgrB gene or acquisition of mcr- 1 or  mcr- 2 genes, and thus, is probably 
caused by the adaptive mechanisms such as porin loss or upregulation of efflux pumps. 
Adaptive colistin resistance mechanisms were previously reported in Enterobacter aerogenes 
but there are no reports so far for K. pneumoniae  [48,49].  Mutations in the two- component 
signalling transduction system phoP/phoQ  or  pmrA/pmrB, regulating genes necessary for 
lipopolysaccharide modifications may play a role in the colistin resistance  [50], but 
investigation of outer membrane lipopolysaccharides was beyond the scope of the present 
study.   Our results are  in disagreement to  the previous studies which found the inactivation 
of mgrB genes or acquisition of mcr genes  as a causative agent for colistin resistance in 
Europe [38, 51]. Emergence of colistin resistance in OXA-48 producing K. pneumoniae was 
previously reported in Tunisia [52]. 
Meropenem reduced susceptibility was transferable in  the majority of isolates indicating 
plasmid location of blaOXA-48 genes.  Furthermore, blaOXA-48 carrying transconjugants were 
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shown to possess L plasmid as their respective donors. However, we did not prove with 
certainty the plasmid location of the blaOXA-48 genes because Southern blotting was not 
performed although the BLAST analyses of the WGS contigs suggest the presence of blaOXA-
48 on plasmids. Moreover, blaOXA-48 carrying  transconjugants obtained in our study did not 
harbour any additional resistance genes similarily  as reported in the previous study  [20]. 
ISEcp1-like element detected in all CTX-M positive isolates was shown previously to play a 
key role in the  mobilization of blaCTX-M genes [39]. 
The majority of the isolates were positive for IS1999 upstream of the blaOXA-48 gene which is 
responsible for the mobilization of blaOXA-48 genes and enhances the expression of the gene. 
Analysis of the flanking regions of blaOXA-48 gene revealed similar structure as previously 
reported by Gianni et al with IS1R element between IS1999 and the OXA-48 encoding gene 
[12].  
PFGE showed the existence of five different K. pneumoniae clusters with isolates from 
different centers and with different β-lactamase content belonging to the same clusters 
indicating transfer of the related strains by patient or staff transfer. The isolates from the same 
center but different clinical wards showed high similarity in the PFGE banding patterns 
pointing out to the cross infections. PFGE patterns did not correlate with resistance gene 
content and the highly related isolates showed different β-lactamase genes. This indicates that 
resistance genes were acquired after the spread of the related isolates in the hospital wards.  
Unlike sixty-seven MBL producing organisms (65 positive for  VIM-1,  seven of which were 
positive also for NDM-1 and  two isolates  positive only for NDM-1)  from the previous study 
conducted in 2013-2014 in four hospital centers in Croatia [17] which demonstrated almost 
identical resistance phenotype, β-lactamase content and PFGE profiles, OXA-48 positive 
organisms from this study showed high variability in antibiotic susceptibilities, β-lactamase 
content and PFGE banding patterns. In the earlier study (2013-2014) OXA-48 was found in 
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combination with VIM-1 and NDM-1 in  two K. pneumoniae isolates from University 
Hospital Center Zagreb and as a sole carbapenemase in one K. pneumoniae isolate from Split 
[17]. Similarily as in recently published nationwide study on early  OXA-48 positive K. 
pneumoniae collected in 2011 to 2012  in Croatia [20] the dissemination of OXA-48 positive 
isolates was polyclonal. The results points out to the fact the vertical transmission of related 
isolates by patient or staff  transfer and probably dissemination of  L  plasmids carrying 
blaOXA-48 genes between different isolates which was previously reported by other authors 
[12] but not confirmed in our study.  In contrast to earlier study in which all OXA-48 strains 
coproduced CTX-M-15 [20], in our investigation only the part of the isolates harboured 
ESBL. Although K. pneumoniae was the dominant species harbouring blaOXA-48 genes in this 
study,  OXA-48 β-lactamase was described for the first time  in C. freundii in Croatia.  
Significant proportion of isolates originated from colonization, raising the concern that 
colonization if unobserved, can act as the potential source of dissemination of OXA-48 
producing organisms within the hospitals. These finding warrants for continous surveillance 
in order to prevent the spread of these isolates in our healthcare system.  
 Further studies are necessary to elucidate if meropenem and imipenem can be administered 
for treatment of infections with isolates showing susceptibility to them.  
The study demonstrated dynamic changes of carbapenem-resistance mechanisms of important 
hospital pathogens like K. pneumoniae or E. cloacae with VIM and NDM as dominant 
carbapenem-resistance mechanism in 2012-2014 and OXA-48 becoming predominant in the 
period 2015 to 2017. We have also shown the complex epidemiology of OXA-48 producing 
Enterobacteriaceae  including cross infections, transmissions of isolates between hospitals and 
polyclonal outbreaks in smaller hospitals.  
Interestingly, two isolates from Pula were obtained from the residents of a nursing home and 
one from the ointment used in the long-term care facility indicating the possibility of 
22 
 
dissemination of carbapenem-resistance determinants into the community. The large 
differences in the prevalence of OXA-48 β-lactamase among the participating centers may 
suggest that Croatia is not yet in an advanced stage of dissemination of OXA-48 or may 
reflect variations in the success of infection control in particular sites.  
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LIST OF ABBREVIATIONS 
MIC-minimum inhibitory concentration, EDTA- Ethylenediaminetetraacetic acid; PCR-
polymerase chain reaction; CAZ-ceftazidime; CTX-cefotaxime; CRO-ceftriaxone; FEP-cefepime; 
IMI-imipenem; MEM-meropenem;  ERT-ertapenem; GM-gentamicin; CIP-ciprofloxacin; AMI –
amikacin; TOB-tobramycin; AZI- azitromycin; LEV-levofloxacin; CXM-cefuroxime; AMC-
amoxicillin-clav.acid; COL-colistin; VAN-vancomycin;  TIG-tigecycline; FOS-fosfomycine; CZ-
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cephazoline; ESBL-inhibitor based test with clavulanic acid for detection of extended-spectrum beta-
lactamases; Amp-C-inhibitor based test with phenyloboronic acid for detection of AmpC beta-
lactamases; BL-beta-lactamase content; CIM-carbapenem- inactivation method;  PBRT-PCR based 
replicon typing; R- released from the hospital; I-improved; D-died, NA-not applicable 
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FIGURE LEGEND 
Fig. S 1. (supplementary material)  Map of Croatia with the location of participating centers.  
Fig  S 2a. (supplementary material) PFGE dendrogram of OXA-48-producing  K. pneumoniae 
isolates. The strain number, protocol number, PFGE cluster,  date of isolation, hospital ward 
and specimen are shown. The cut of value of 80% was used to define a clone.  The subclones 
differed in one or two bands. Abbreviations: NT-not tested, S- singleton 
Fig. 2b . PFGE dendrogram of  OXA-48 producing E. cloacae isolates. The strain number, 
protocol number, PFGE cluster,  date of isolation, hospital ward and specimen are shown. The 
cut of value of 80% was used to define a clone.  The subclones differed in one or two bands. 
Abbreviations: NT-not tested, S- singleton 
 
 
 
 
 
 
No CENTRE 
AND  
ISOLATE 
NUMBER 
SPECIMEN DEPARTMENT    DATE ESBL AMPC Hodge CIM CAZ CTX CRO FEP IPM MEM ERT GM CIP COL Other β-
lactamases 
and qnr  
genes 
PFGE 
cluster 
Type of infection Antibiotic 
treatment 
Clinical 
outcome 
 Klebsiella pneumoniae                     
1 Osijek  
OS 5 
(2977) 
Catheter 
urine 
Neurology 26.04.2016 + + + - 64 >128 >128 >128 0.5 1 4 0.25 >128 1 SHV 
OXA-1 
CTX-M 
TEM 
Qnr A 
 
KIa 
  
 
Colonization   No        R 
2 Osijek  
OS 3 
(4568) 
 
Pharyngeal 
swab 
Haematology 14.03.2016. - - + + 0.5 0.25 0.25 0.12 0.06 4 4 0.5 >128 1 SHV KIa Colonization  COL        R 
3 Osijek  
OS 17 
(16859) 
Tracheal 
aspirate 
ICU 17.10.2016. + - + + >128 >128 >128 8 0.5 0.25 4 0.5 >128 0.25 SHV 
CTX-M 
Qnr B 
 
KIb Pneumonia MEM        D 
4 Osijek  
OS 10 
(4700) 
 
Urine Cardiology 05.07.2016. + - + + 64 64 >128 32 0.25 0.12 2 0.5 >128 1 SHV 
CTX-M 
TEM 
KIc UTI MEM           R 
5 Osijek  
OS 4 
(1603) 
Blood ICU 12.04.2016 + + + - 32 >128 >128 >128 64 32 32 0.5 >128 1 SHV 
OXA-1 
CTX-M 
Qnr B 
 
KId Sepsis  MEM  
 VAN 
       D 
6 Osijek 
OS 19  
(8269) 
 
Catheter 
urine 
Infectology 01.12.2016. + - + + 32 64 64 16 8 8 32 >128 32 0.06 SHV 
CTX-M 
KIe UTI  IMI       D 
7 Osijek  
OS 22  
(20566) 
 
Abdominal 
swab 
Abdominal 
surgery 
14.12.2016 - - + + 0.25 0.5 0.5 0.06 0.12 0.25 1 0.25 >128 2 TEM 
SHV 
 
KIe Peritonitis TIG 
COL 
 
      D 
8 Osijek  
OS 15 
(13744) 
 
Axillar  
swab 
ICU 23.08.2016 - - + + 0.5 0.25 0.25 0.12 0.25 0.5 0.5 4 32 0.5 SHV-1 
Qnr B 
 
KIe Colonization FEP       D 
9 Osijek 
OS 21  
(8499) 
Urine Neurosurgery 6.12. 2016 + 
 
- + + 32 >128 >128 4 0.06 0.25 1 0.12 >128 64 SHV 
CTX-M 
Qnr A, B 
 
KIe UTI MEM       D 
                        
10 Osijek  
OS2  
(1365) 
 
 
Blood Gastroenterology 28.03.2016 - - + + 8 1 0.5 0.25 0.25 1 2 0.25 >128 1 SHV-1 
OXA-1 
KIe Sepsis  CIP  
 MET 
       R 
                         
11 Osijek 
3177 
Tracheal 
aspirate  
 Internal clinic –
ICU                                                          
 
22.02.2016. - - + + 0.12 0.25 0.5 0.25 0.12 0.12 0.5 0.12 0.25 0.25 SHV-1 
 
KIe Pneumonia   AMC  
  AMI 
        D 
12 Osijek  
OS 18 
(17068) 
Tracheal 
aspirate 
ICU 20. 10. 
2016.  
+ - + + 64 >128 >128 8 0.5 0.5 8 0.25 >128 0.25 SHV 
CTX.-M 
Qnr B 
 
KIf Pneumonia   TZP        R 
13 Osijek 
OS 419 
Tracheal 
aspirate 
ICU 10.01.2016. + - + + >128 >128 >128 >128 16 32 32 0.5 >128 1 SHV 
TEM 
CTX-M 
KIf Pneumonia    IMI        D 
14 Split      
UR 5429  
urine Internal clinic 24.03.2017. + - + + >128 >128 >128 64 4 16 32 1 >128 0.12 SHV 
CTX-M 
KIg UTI   MEM 
  AMI 
 
      I 
15 Split      
UR 5429  
urine Internal clinic 24.03.2017. + - + + >128 >128 >128 64 4 16 32 1 >128 0.12 SHV 
CTX-M 
KIg UTI    MEM 
   AMI 
 
      I 
16 Split      
DG 3759 
Wound 
swab 
ICU 11.04.2017. + - + + 64 >128 >128 >128 4 16 4 0.12 >128 0.12 SHV 
CTX-M 
KIg Postoperative 
osteomyelitis 
   COL 
   VAN 
   MEM 
 
      I 
                        
17 Split  
UR7213 
 
urine Infective clinic 21.04.2017. + - + + 64 >128 >128 32 2 16 8 0.12 >128 0.12 SHV 
CTX-M 
KIg Osteomyelitis   
UTI 
    FOS       I 
18 Split      
UR 5817  
urine Neurosurgery 30.03.2017. + - + + >128 >128 >128 >128 4 16 16 4 >128 0.5 SHV 
CTX-M    
Qnr B 
 
KIg UTI     GM       R 
19 Pula   
322-1 
Lanolin 
cream 
Nursing  home 09.09.2016. + - + + 16 >128 64 16 2 4 4 0.5 32 0.5 SHV 
 TEM 
CTX-M      
Qnr B 
 
KIh Colonization      None         R 
20 Osijek  
OS 8 
(4063) 
Catheter 
urine 
Neurosurgery 09.06.2016 + - + + 8 >128 >128 4 2 2 4 1 >128 0.5 SHV-1 
OXA-1 
CTX-M-
15  
KIIa   UTI     CIP        R 
                        
21 Zagreb 
VG-8166 
urine Urology 19.02.2015. + - + - >128 >128 >128 >128 1 0.5 16 >128 32 0.003 SHV-1 
CTX-M-
15 
 
KIIa UTI   MEM        R 
                        
22 Osijek  
OS 11 
(11461) 
 
Abdominal 
swab 
Abdominal 
surgery 
12.07.2016 - - + + 0.25 0.5 0.25 0.12 0.25 0.12 2 0.5 >128 1 SHV 
 
KIIb Peritonitis   AMC 
   MET 
   GEN 
     D 
   
 
                     
23 UHC 
ZGB  
149765 
 
 
Perineal 
swab 
Internal clinic 17.08.2016 - 
 
 
- + + 0.25 0.25 0.25 0.06 4 4 4 0.25 1 0.12 SHV KIIb Pleuropneumo
nia 
    MEM        R 
 24      Pula          
16780-1 
Catheter 
urine 
Neurology 21.07.2016. + - + + 16 >128 >128 64 32 64 32 0.25 >128 0.5 SHV-1 
CTX-M-
15 Qnr B 
 
KIIc Colonization        None          R 
25 Pula 
15636-1 
Perineal 
swab 
Infectology 08.04.2017. + - + + 16 64 32 2 2 8 4 0.25 >128 0.5 SHV 
TEM 
CTX-M    
Qnr B 
 
KIIc Colonization       None          D 
26 Slavonski 
brod 
15307 
Urine ICU 15.05.2017. + - + + 4 32 8 8 1 1 4 32 >128 0.12 SHV-1 
CTX-M-
15 TEM-1 
KIIc UTI    AMC 
    AZI  
    ERT    
 
         D                                                                                                                            
27 Slavonski 
brod 
16098 
 
Urine Neurosurgery 22.05.2017. + - + + 32 >128 >128 >128 1 0.5 2 32 >128 0.25 SHV 
CTX-M 
TEM 
KIIc UTI  CZ, LEV 
ERT, AMI 
 
         R 
28 Split        
KK 3602 
Rectal swab Neurosurgery 13.4.2016. + - + + 64 >128 >128 >128 1 4 8 0.12 >128 0.12 SHV 
CTX-M 
S Pneumonia   COL 
  MEM 
 AMI 
 
        I 
 
 
UHC 
ZGB 
190807 
Urine Internal clinic 
(farmacology)           
17.10.2016 - 
 
 
 
- + + 4 0.5 0.12 0.06 32 32 64 0.12 2 1 SHV-1 KIIIa Urosepsis    CXM         I 
30 Rijeka 
012552 
External  
ear swab 
Dermatovenerology 07.03.2016. - - + + 4 1 1 1 4 2 16 0.12 2 1 SHV 
Qnr B 
 
KIIIb    Purulent      
otitis media 
  TOB 
  MOX drop 
 
         R 
31 Osijek 
10059 
Tracheal 
aspirate  
 
Surgical ICU 31.07.2015. - - + + 4 1 1 0.5 2 1 16 0.25 2 0.5 SHV   
Qnr B 
 
KIIIc Pneumonia   MEM          I 
32 Osijek  
OS 7 
(8127) 
Pharyngeal 
swab 
 
ICU 27.05.2016 - - + + 4 1 2 0.12 2 1 8 0.5 0.25 1 SHV  
Qnr B 
 
KIIId Colonization   No         R 
                        
 Table 1.a Antibiotic susceptibility, resistance genes content, genotypes of  Klebsiella pneumoniae isolates  and clinical data. 
 
Abbreviations: CAZ-ceftazidime; CTX-cefotaxime; CRO-ceftriaxone; FEP-cefepime; IMI-imipenem; MEM-meropenem;  ERT-ertapenem; GM-gentamicin; 
CIP-ciprofloxacin; AMI –amikacin; TOB-tobramycin; AZI- azitromycin; LEV-levofloxacin; CXM-cefuroxime; AMC-amoxicillin-clav.acid; COL-colistin; 
VAN-vancomycin;  TIG-tigecycline; FOS-fosfomycine; CZ-cephazoline; ESBL-inhibitor based test with clavulanic acid for detection of extended-spectrum 
                        
33 Zagreb 
VG-
16/3885 
 
Blood  ICU 13.12.2016. + - + - >128 >128 >128 16 0.5 4 8 >128 0.5 1 TEM-1 
SHV-11 
CTX-M-15 
KIIIe Sepsis  MEM         R 
34 
 
 
Pula  
15889 
Catheter 
urine 
Neurology 30.06.2017. + + + - 16 >128 >128 64 32 64 32 0.25 >128 0.5 SHV 
CTX-M-
TEM 
Qnr B 
 
KIVa Colonization None                             R                             
35 
 
Slavonski 
brod 
24889 
Perineal 
swab 
Surgery 15.03.2017. + + + + >128 >128 >128 64 32 32 64 >128 >128 128 SHV 
CTX-M 
TEM 
Qnr B 
KIVa Colonization     AMI       R 
36 
 
Osijek  
OS 13 
(4988) 
 
Catheter 
urine 
ICU 16.07.2016 + - + - 32 64 >128 32 0.25 0.25 1 0.5 >128 1 SHV 
CTX-M 
S UTI     MEM       D 
37 
 
Split  
UR 
22272 
Urine  Haematology 31.12.2016. + 
 
 
- + + 32 >128 >128 >128 4 8 16 0.25 >128 0.12 SHV-11 
TEM-1 
CTX-M-
15 Qnr B 
KVa Pyelonephritis    MEM  
    AMI 
      I 
38 
 
Osijek  
OS 16 
(15299) 
Wound 
swab 
Abdominal 
surgery 
19.09.2016. + - + + 32 >128 >128 16 1 0.5 4 0.25 >128 1 SHV 
CTX-M 
Qnr B 
 
KVa Wound 
infection 
   AMI  
   MEM 
      R 
39 
 
Osijek  
OS 9 
(10454) 
 
 
 
Intraoperative 
swab 
Neurosurgery 24.06.2016. - 
 
 
 
- + + 0.5 0.25 0.25 0.25 1 0.5 0.25 0.5 >128 0.25 SHV        
Qnr B       
S Wound 
infection 
  FEP       R 
40 Osijek 
OS 25  
(9585) 
Pharyngeal 
swab 
Neurology 5.6.2017. + - + + 32 >128 >128 >128 0.5 0.5 0.5 0.06 128 2 TEM 
SHV 
CTX-M 
Qnr B 
 
NT Colonization    CIP  
   IMI 
     R 
beta-lactamases; Amp-C-inhibitor based test with phenyloboronic acid for detection of AmpC beta-lactamases; BL-beta-lactamase content; CIM-carbapenem 
inactivation method; PFGE-pulsed field gel electrophoresis  NT-not tested; S-singleton; ICU-intensive care unit;  RES-resistance genes; R- released from the 
hospital; I-improved; D-died.  
 
 
 
 
 No  CENTRE                       SPECIMEN              DEPARTMENT                      DATE                           ESBL          AMPC           Hodge           CIM                   CAZ          CTX              CRO               FEP           IPM           MEM                 ETP                           
       AND 
       ISOLATE  
       NUMBER 
 
GM        CIP                COL Other β-
lactamases 
and qnr  
genes 
         PFGE 
         cluster  
Type of 
infection 
                     Clinical 
         outcome 
Enterobacter cloacae          
1 Osijek   
OS 
14(5824) 
 
Catheter 
urine 
 
Internal clinic  23.08.2016. + + + + >128 64 >128 64 2 4 8 32 8 1 CTX-M               EIa              UTI               COL, RIF                      D 
  Qnr B                                                             
                                                                           
2 Osijek  
7766 
Catheter 
urine 
 
Neurology 17.11.2015. + + 
 
+ + 32 >128 >128 32 2 1 16 32 8 0.5 CTX-M            
                   
 
EIb            NA                 NA                     NA 
3 Pula       
17504  
Urine Oncology 23.08.2017. + + + + >128 >128 >128 64 4 4 16 >128 >128 2 OXA-1 
CTM-15 
TEM-1  
ACT-7 
 
EIc         Col              NA                        D      
 
4 
 
Slavonski 
Brod  
30676 
 
Urine 
 
ICU 
 
 
 
+ 
 
+ 
 
+ 
 
+ 
 
32 
 
>128 
 
>128 
 
32 
 
0.25 
 
0.5 
 
1 
 
>128 
 
2 
 
 
    
TEM-1 b                   EIc            UTI           AMC                             R 
CTX-M-15 
OXA-1 
ACT-7 
 
 
5 Split  HK 
1076 
Blood 
culture 
Neurosurgery 25.01.2016. + - + + >128 >128 >128 >128 4 8 16 4 >128 0.12 CTX-M               EId        Pneumonia      MEM, VAN           I      
                                                                                     
E.coli                        
1 Pula       
18464  
urine Urology 28.08.2017. - - + + 1 0.5 0.25 0.12 16 2 4 32 >128 2 TEM-1                         Colonization            No                      R   
Qnr B 
 
2 Osijek  
OS 24 
(9322) 
Wound 
swab 
 
Traumatology 30.05.2017. - - + + 0.12 0.5 0.5 0.12 0.5 0.5 0.5 0.06 128 2                                       Wound                  AMC                   R 
                                      infection                MET 
                                                                    MEM 
                                                                    VAN 
Citrobacter freundii                    
1 Osijek  
20  
(19409) 
Wound 
swab 
 
Abdominal 
surgery 
28.11.2016. - + + + 1 0.5 0.5 0.06 0.06 0.06 1 0.25 0.06 1 CMY NA  NA                   D    
Antibiotic treatment 
  
 
Table 1.b Antibiotic susceptibility, resistance genes content, genotypes of  Enterobacter cloacae, Eshcerichia coli and Citrobacter freundii isolates  and 
clinical data. 
 
Abbreviations: CAZ-ceftazidime; CTX-cefotaxime; CRO-ceftriaxone; FEP-cefepime; IMI-imipenem; MEM-meropenem;  ERT-ertapenem; GM-gentamicin; 
CIP-ciprofloxacin; AMI –amikacin; TOB-tobramycin; AZI- azitromycin; LEV-levofloxacin; CXM-cefuroxime; AMC-amoxicillin-clav.acid; COL-colistin; 
VAN-vancomycin;  TIG-tigecycline; FOS-fosfomycine; CZ-cephazoline; ESBL-inhibitor based test with clavulanic acid for detection of extended-spectrum 
beta-lactamases; Amp-C-inhibitor based test with phenyloboronic acid for detection of AmpC beta-lactamases; BL-beta-lactamase content; CIM-carbapenem 
inactivation method;  R- released from the hospital; I-improved; D-died, ICU-intensive care unit;  NA-not applicable 
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Fig  S 2a. (supplementary material) PFGE dendrogram of OXA-48-producing  K. pneumoniae 
isolates. The strain number, protocol number, PFGE cluster,  date of isolation, hospital ward 
and specimen are shown. The cut of value of 80% was used to define a clone.  The subclones 
differed in one or two bands. Abbreviations: NT-not tested, S- singleton 
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Fig. S 2b . (supplementary material).  PFGE dendrogram of  OXA-48 producing E. cloacae 
isolates. The strain number, protocol number, PFGE cluster,  date of isolation, hospital ward 
and specimen are shown. The cut of value of 80% was used to define a clone.  The subclones 
differed in one or two bands. Abbreviations: NT-not tested, S- singleton 
 
